Gallbladder cancer (GBC) is an extremely aggressive biliary tract malignancy characterized by silent early progression, ...

Karyopharm Therapeutics (NASDAQ:KPTI) said it entered 2026 with several near-term clinical and regulatory catalysts, led by ...

Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib ...

FDA accelerated approval covers relapsed/refractory MCL after ≥2 lines including a BTK inhibitor, positioning sonrotoclax as ...

Detailed price information for Aptose Biosciences Inc (APTOF) from The Globe and Mail including charting and trades.

The FDA approved sonrotoclax for R/R mantle cell lymphoma. Nurses must manage a 4-week dose ramp-up to prevent TLS for patients after prior BTK therapy. Oncology nurses have a new therapeutic option ...

Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company ...

Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancerNew ...

Detailed price information for Aptevo Therapeutics Inc (APVO-Q) from The Globe and Mail including charting and trades.

Program Enters Final Stage of Dose Optimization Data Continue to Demonstrate Strong Clinical Activity and Favorable Safety Across an Expanding Frontline Dataset SEATTLE, WA / ACCESS Newswire / May 6, ...

A new risk model proves to be effective at identifying the risk for a rare genetic condition that increases predisposition for cancer.